Accordingly, thrombopoietin receptor agonists (TPO-RAs), including eltrombopag (EPAG), romiplostim, and avatrombopag, have been approved for the treatment of chronic immune thrombocytopenia (ITP) and/or aplastic anemia (AA) (12–14). The gene discussed is TPO; the disease is autoimmune thrombocytopenic purpura.